Literature DB >> 20334347

Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones.

J Nicole Burns1, Susan D Orwig, Julia L Harris, J Derrick Watkins, Douglas Vollrath, Raquel L Lieberman.   

Abstract

Mutations in myocilin cause an inherited form of open angle glaucoma, a prevalent neurodegenerative disorder associated with increased intraocular pressure. Myocilin forms part of the trabecular meshwork extracellular matrix presumed to regulate intraocular pressure. Missense mutations, clustered in the olfactomedin (OLF) domain of myocilin, render the protein prone to aggregation in the endoplasmic reticulum of trabecular meshwork cells, causing cell dysfunction and death. Cellular studies have demonstrated temperature-sensitive secretion of myocilin mutants, but difficulties in expression and purification have precluded biophysical characterization of wild-type (wt) myocilin and disease-causing mutants in vitro. We have overcome these limitations by purifying wt and select glaucoma-causing mutant (D380A, I477N, I477S, K423E) forms of the OLF domain (228-504) fused to a maltose binding protein (MBP) from E. coli . Monomeric fusion proteins can be isolated in solution. To determine the relative stability of wt and mutant OLF domains, we developed a fluorescence thermal stability assay without removal of MBP and provide the first direct evidence that mutated OLF is folded but less thermally stable than wt. We tested the ability of seven chemical chaperones to stabilize mutant myocilin. Only sarcosine and trimethylamine N-oxide were capable of shifting the melting temperature of all mutants tested to near that of wt OLF. Our work lays the foundation for the identification of tailored small molecules capable of stabilizing mutant myocilin and promoting secretion to the extracellular matrix, to better control intraocular pressure and to ultimately delay the onset of myocilin glaucoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20334347      PMCID: PMC2874607          DOI: 10.1021/cb900282e

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  55 in total

Review 1.  The osmophobic effect: natural selection of a thermodynamic force in protein folding.

Authors:  D W Bolen; I V Baskakov
Journal:  J Mol Biol       Date:  2001-07-27       Impact factor: 5.469

Review 2.  Quality control in the endoplasmic reticulum.

Authors:  Lars Ellgaard; Ari Helenius
Journal:  Nat Rev Mol Cell Biol       Date:  2003-03       Impact factor: 94.444

3.  Expression and characterization of the olfactomedin domain of human myocilin.

Authors:  Ildikó Nagy; Mária Trexler; László Patthy
Journal:  Biochem Biophys Res Commun       Date:  2003-03-14       Impact factor: 3.575

4.  A cellular assay distinguishes normal and mutant TIGR/myocilin protein.

Authors:  Z Zhou; D Vollrath
Journal:  Hum Mol Genet       Date:  1999-11       Impact factor: 6.150

5.  Characterization of myocilin-myocilin interactions.

Authors:  M P Fautsch; D H Johnson
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

6.  In vitro localization of TIGR/MYOC in trabecular meshwork extracellular matrix and binding to fibronectin.

Authors:  Mark S Filla; Xuyang Liu; Thai D Nguyen; Jon R Polansky; Curtis R Brandt; Paul L Kaufman; Donna M Peters
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-01       Impact factor: 4.799

7.  Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells.

Authors:  Myung Kuk Joe; Seongsoo Sohn; Wonhee Hur; Younkyong Moon; Young Ran Choi; Changwon Kee
Journal:  Biochem Biophys Res Commun       Date:  2003-12-19       Impact factor: 3.575

Review 8.  Therapeutic approaches to protein-misfolding diseases.

Authors:  Fred E Cohen; Jeffery W Kelly
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

9.  Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function.

Authors:  B S Kim; O V Savinova; M V Reedy; J Martin; Y Lun; L Gan; R S Smith; S I Tomarev; S W John; R L Johnson
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

Review 10.  Biological and chemical approaches to diseases of proteostasis deficiency.

Authors:  Evan T Powers; Richard I Morimoto; Andrew Dillin; Jeffery W Kelly; William E Balch
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

View more
  34 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  Differential Misfolding Properties of Glaucoma-Associated Olfactomedin Domains from Humans and Mice.

Authors:  Athéna C Patterson-Orazem; Shannon E Hill; Yiming Wang; Iramofu M Dominic; Carol K Hall; Raquel L Lieberman
Journal:  Biochemistry       Date:  2019-03-12       Impact factor: 3.162

3.  Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma.

Authors:  Dustin J E Huard; Vincent M Crowley; Yuhong Du; Ricardo A Cordova; Zheying Sun; Moya O Tomlin; Chad A Dickey; John Koren; Laura Blair; Haian Fu; Brian S J Blagg; Raquel L Lieberman
Journal:  ACS Chem Biol       Date:  2018-02-20       Impact factor: 5.100

4.  Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma.

Authors:  Andrew R Stothert; Amirthaa Suntharalingam; Dustin J E Huard; Sarah N Fontaine; Vincent M Crowley; Sanket Mishra; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

5.  Stable calcium-free myocilin olfactomedin domain variants reveal challenges in differentiating between benign and glaucoma-causing mutations.

Authors:  Shannon E Hill; Michelle S Kwon; Mackenzie D Martin; Amirthaa Suntharalingam; Anthony Hazel; Chad A Dickey; James C Gumbart; Raquel L Lieberman
Journal:  J Biol Chem       Date:  2019-07-02       Impact factor: 5.157

6.  The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder.

Authors:  J Nicole Burns; Katherine C Turnage; Chandler A Walker; Raquel L Lieberman
Journal:  Biochemistry       Date:  2011-06-09       Impact factor: 3.162

7.  The glaucoma-associated olfactomedin domain of myocilin forms polymorphic fibrils that are constrained by partial unfolding and peptide sequence.

Authors:  Shannon E Hill; Rebecca K Donegan; Raquel L Lieberman
Journal:  J Mol Biol       Date:  2013-12-09       Impact factor: 5.469

8.  Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism.

Authors:  Amirthaa Suntharalingam; Jose F Abisambra; John C O'Leary; John Koren; Bo Zhang; Myung Kuk Joe; Laura J Blair; Shannon E Hill; Umesh K Jinwal; Matthew Cockman; Adam S Duerfeldt; Stanislav Tomarev; Brian S J Blagg; Raquel L Lieberman; Chad A Dickey
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

9.  Epitope mapping of commercial antibodies that detect myocilin.

Authors:  Athéna C Patterson-Orazem; Shannon E Hill; Michael P Fautsch; Raquel L Lieberman
Journal:  Exp Eye Res       Date:  2018-05-09       Impact factor: 3.467

10.  Tracking unfolding and refolding reactions of single proteins using atomic force microscopy methods.

Authors:  Paul J Bujalowski; Andres F Oberhauser
Journal:  Methods       Date:  2013-03-20       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.